NexgenRx Inc. Stock

NXG

CA65337X1042

Investment Management & Fund Operators

Market Closed - Toronto S.E. Other stock markets 15:22:09 2026-07-24 EDT			5-day change	1st Jan Change
0.7000 ^CAD	+7.69%		+27.27%	+75.00%

05-22	Earnings Flash (NXG.V) NexgenRx Reported Q1 Total Revs $5.0M, Up 11.6% YoY; Net Income and EBITDA Improved	MT
05-21	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

NexgenRx Inc. is a Canada-based independent full-service third-party administrator and technology solutions provider. The Company administers, adjudicates and pays drug, dental and other extended healthcare claims for the beneficiaries of health benefit plans underwritten by its customers, using proprietary computer software and also providing ancillary services. It offers plan sponsors, providers and patient support program/drug manufacturers a full suite of software-as-a-service solutions. The Companyâ€™s products include NexSys, NexAdmin, and NexPSPAssist. The NexSys is a fully integrated rules based adjudication platform for secure real-time processing of drug, dental and extended health benefit claims. Its NexAdmin product enables sponsors to take complete control of benefit plan administration. The NexPSPAssist service helps patient support programs (PSP) to optimize their deliverables to their manufacturer clients.

Employees

Sector

Investment Management & Fund Operators

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	$0.7000	+7.69%	87,005
26-07-23	$0.6500	0.00%	39,125
26-07-22	$0.6500	0.00%	10,291
26-07-21	$0.6500	-1.52%	2,728
26-07-20	$0.6600	+20.00%	86,597

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

As early as today, start finding the best investment opportunities!

Market Cap	49.78M 35.32M 31.03M 28.86M 26.48M 3.41B 50.54M 342M 134M 1.67B 133M 130M 5.78B	P/E 2024	55x	P/E 2025	28.6x
Enterprise Value	45.37M 32.19M 28.28M 26.31M 24.14M 3.11B 46.06M 312M 122M 1.52B 121M 118M 5.27B	EV / Sales 2024	1.12x	EV / Sales 2025	1.34x
Free-Float	63.03%	Yield 2024	3.64%	Yield 2025	3.75%

05-22	Earnings Flash (NXG.V) NexgenRx Reported Q1 Total Revs $5.0M, Up 11.6% YoY; Net Income and EBITDA Improved	MT
05-21	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-19	NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026	CI
03-31	NexgenRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-10	NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025	CI
11-21	NexgenRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-21	NexgenRx Q3 Revenue Rises 13%, Net Income and EBITDA Improve	MT
11-20	Earnings Flash (NXG.V) NexgenRx Reported Q3 Revenue $4.6M	MT
25-08-18	NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025	CI
25-08-12	NexgenRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-15	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-17	Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025	CI
24-11-25	Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024	CI

1 day	+7.69%
1 week	+27.27%
Current month	+52.17%
1 month	+50.54%
3 months	+79.49%
6 months	+75.00%
Current year	+75.00%

1 week	0.56	0.75
1 month	0.45	0.75
Current year	0.29	0.75
1 year	0.29	0.75
3 years	0.18	0.75
5 years	0.18	0.75
10 years	0.14	0.75

Manager	Title	Age	Since
Ronald Loucks CEO	Chief Executive Officer	-	2003-03-12
Phoebe Lee DFI	Director of Finance/CFO	-	-
Kelly Elher DFI	Director of Finance/CFO	63	2016-12-04

NexgenRx Inc. Stock

Stocks

NXG

CA65337X1042

Investment Management & Fund Operators

Valuation: NexgenRx Inc.

Chart: NexgenRx Inc.

Latest news : NexgenRx Inc.

Quotes and Performance

Course Extremes

Managers and Directors: NexgenRx Inc.

Latest insider transactions

Other Investment Management & Fund Operators

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Ronald Loucks BRD	Director/Board Member	-	2003-03-12
Thomas Corcoran CHM	Chairman	-	2006-03-06
Charles Burns BRD	Director/Board Member	-	2017-06-15

Date	Insider	Type	Quantity	% Market Cap.
10/1/24	Paul Everett Crossett	Buy	14,500	0.0204%
9/17/24	Paul Everett Crossett	Buy	20,000	0.0281%
9/13/24	Paul Everett Crossett	Buy	15,000	0.0211%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEXGENRX INC.	+7.69%	+27.27%	+105.88%	+133.33%	35.35M
BLACKROCK, INC.	+1.78%	-1.54%	-6.02%	+41.51%	164B
UBS GROUP AG	+0.17%	-0.54%	+39.22%	+125.29%	161B
BANK OF NEW YORK MELLON CORPORATION (THE)	-0.75%	+1.13%	+57.46%	+254.71%	108B
BROOKFIELD CORPORATION	+1.22%	-3.92%	-4.86%	+87.64%	95.28B
BROOKFIELD ASSET MANAGEMENT LTD.	+1.43%	-3.51%	-24.37%	+45.11%	74.07B
STATE STREET CORPORATION	+0.65%	+1.59%	+64.17%	+162.12%	50.93B
AMERIPRISE FINANCIAL, INC.	+1.69%	+0.20%	+1.50%	+49.12%	46.75B
3I GROUP PLC	+3.14%	+7.07%	-33.45%	+39.22%	36.91B
NORTHERN TRUST CORPORATION	+1.44%	-2.25%	+38.83%	+130.40%	33.03B
Average	+1.85%	-0.72%	+23.84%	+106.85%	76.92B
Weighted average by Cap.	+0.96%	-1.25%	+16.43%	+107.12%

	2024	2025
Net sales	16.48M 11.69M 10.27M 9.55M 8.76M 1.13B 16.73M 113M 44.22M 553M 43.88M 42.95M 1.91B	17.93M 12.72M 11.18M 10.4M 9.54M 1.23B 18.21M 123M 48.13M 602M 47.77M 46.75M 2.08B
Net income	615K 436K 383K 356K 327K 42.1M 624K 4.22M 1.65M 20.63M 1.64M 1.6M 71.41M	1.29M 915K 804K 748K 686K 88.34M 1.31M 8.86M 3.46M 43.29M 3.44M 3.36M 150M
Net Debt	-1.17M -831K -730K -679K -623K -80.26M -1.19M -8.05M -3.15M -39.33M -3.12M -3.05M -136M	-4.41M -3.13M -2.75M -2.56M -2.35M -302M -4.48M -30.3M -11.84M -148M -11.75M -11.5M -513M